Laurence Duquenne

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Venues

RMD open

Annals of internal medicine

Expert opinion on drug safety

Rheumatology (Oxford, England)

Leeds Teaching Hospitals NHS Trust

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Leeds Teaching Hospitals NHS Trust Oct 09 2017

United Kingdom

Clinical research Fellow :: LIRMM

Publications

Andrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, Sana Sharrack, Laurence Duquenne, Jacqueline L Nam, Michael Mahler, Paul Emery
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD open 10 (2) (2024)
Andrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, Sana Sharrack, Laurence Duquenne, Jacqueline L Nam, Michael Mahler, Paul Emery
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD open 10 (2) (2024)
Andrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, Sana Sharrack, Laurence Duquenne, Jacqueline L Nam, Michael Mahler, Paul Emery
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD open 10 (2) (2024)
Andrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, Sana Sharrack, Laurence Duquenne, Jacqueline L Nam, Michael Mahler, Paul Emery
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD open 10 (2) (2024)
Andrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, Sana Sharrack, Laurence Duquenne, Jacqueline L Nam, Michael Mahler, Paul Emery
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD open 10 (2) (2024)
Innocent Chidi Anioke, Laurence Duquenne, Rekha Parmar, Kulveer Mankia, Farag Shuweihdi, Paul Emery, Frederique Ponchel
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals. Rheumatology (Oxford, England) (2023)
Laurence Duquenne, Elizabeth M A Hensor, Michelle Wilson, Leticia Garcia-Montoya, Jacqueline L Nam, Jianhua Wu, Kate Harnden, Innocent Chidi Anioke, Andrea Di Matteo, Rahaymin Chowdhury, Navkiran Sidhu, Frederique Ponchel, Kulveer Mankia, Paul Emery
Predicting Inflammatory Arthritis in At-Risk Persons: Development of Scores for Risk Stratification. Annals of internal medicine (2023)
Frederique Ponchel, Laurence Duquenne, Xuanxiao Xie, Diane Corscadden, Farag Shuweihdi, Kulveer Mankia, L A Trouw, Paul Emery
Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals. RMD open 8 (2) (2022)
Frederique Ponchel, Laurence Duquenne, Xuanxiao Xie, Diane Corscadden, Farag Shuweihdi, Kulveer Mankia, L A Trouw, Paul Emery
Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals. RMD open 8 (2) (2022)
Frederique Ponchel, Laurence Duquenne, Xuanxiao Xie, Diane Corscadden, Farag Shuweihdi, Kulveer Mankia, L A Trouw, Paul Emery
Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals. RMD open 8 (2) (2022)
Laurence Duquenne, Hanna Gul, Paul Emery
Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view. Expert opinion on drug safety 18 (1) (2018)

Laurence Duquenne.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Laurence Duquenne